Kozobolis Vassileios, Panos Georgios D, Konstantinidis Aristeidis, Labiris Georgios
Department of Ophthalmology, University General Hospital of Evros, Alexandroupolis - Greece.
Eye Institute of Thrace, School of Medicine, University of Thrace, Alexandroupolis - Greece.
Eur J Ophthalmol. 2017 Mar 10;27(2):160-163. doi: 10.5301/ejo.5000826. Epub 2016 Jul 16.
To compare the efficiency of brinzolamide/brimonidine fixed combination vs the dorzolamide/timolol fixed combination.
Forty-four eyes of 44 patients were divided in 2 groups treated either with dorzolamide/timolol twice a day (group A) or with brinzolamide/brimonidine twice a day (group B). Complete ophthalmic examination including Goldmann applanation tonometry was performed before treatment administration and 1, 4, 8, and 12 weeks afterwards. The intraocular pressure (IOP) was measured twice a day (morning at 9 AM and afternoon at 4 PM).
At the end of the follow-up period (12 weeks), mean morning IOP reduction was 7.0 ± 2.8 mm Hg in group A and 8.4 ± 1.9 mm Hg in group B. A significant difference was found (p = 0.0343). In contrast, mean afternoon IOP reduction was 8.6 ± 2.7 mm Hg in group A and 7.9 ± 1.6 mm Hg in group B and no significant difference was found (p = 0.3413). No significant adverse effects were observed in either group.
Brinzolamide/brimonidine seems to be an effective and safe alternative β-blocker free fixed combination, especially for patients with comorbidities, having its own antihypertensive profile.
比较布林佐胺/溴莫尼定固定复方制剂与多佐胺/噻吗洛尔固定复方制剂的疗效。
44例患者的44只眼被分为两组，分别接受一天两次的多佐胺/噻吗洛尔治疗（A组）或一天两次的布林佐胺/溴莫尼定治疗（B组）。在给药前以及给药后1、4、8和12周进行包括Goldmann压平眼压测量法在内的完整眼科检查。每天测量两次眼压（上午9点和下午4点）。
在随访期结束时（12周），A组早晨眼压平均降低7.0±2.8mmHg，B组为8.4±1.9mmHg。发现有显著差异（p = 0.0343）。相比之下，A组下午眼压平均降低8.6±2.7mmHg，B组为7.9±1.6mmHg，未发现显著差异（p = 0.3413）。两组均未观察到显著不良反应。
布林佐胺/溴莫尼定似乎是一种有效且安全的不含β受体阻滞剂的固定复方制剂，尤其适用于有合并症的患者，具有其自身的降压特点。
